Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (327) 327
postremission therapy (282) 282
hematology (260) 260
adult (234) 234
middle aged (233) 233
female (222) 222
male (221) 221
acute myelogenous leukemia (209) 209
oncology (206) 206
index medicus (170) 170
adolescent (156) 156
remission induction (142) 142
treatment outcome (140) 140
aged (137) 137
leukemia, myeloid, acute - therapy (118) 118
acute myeloid-leukemia (115) 115
antineoplastic combined chemotherapy protocols - therapeutic use (115) 115
acute myeloid leukemia (113) 113
bone-marrow-transplantation (111) 111
leukemia, myeloid, acute - mortality (108) 108
disease-free survival (104) 104
prognosis (100) 100
transplantation (96) 96
chemotherapy (95) 95
stem-cell transplantation (89) 89
intensive chemotherapy (87) 87
leukemia, myeloid, acute - drug therapy (87) 87
acute disease (82) 82
postremission chemotherapy (80) 80
aml (79) 79
survival analysis (79) 79
high-dose cytarabine (78) 78
transplantation, homologous (77) 77
acute nonlymphocytic leukemia (75) 75
cytarabine - administration & dosage (75) 75
retrospective studies (70) 70
young adult (70) 70
leukemia, myeloid, acute - genetics (67) 67
1st complete remission (63) 63
hematopoietic stem cell transplantation (63) 63
survival rate (60) 60
adults (55) 55
cancer (55) 55
group-b (52) 52
recurrence (52) 52
leukemia, myeloid - drug therapy (50) 50
risk factors (49) 49
stem cells (49) 49
transplantation, autologous (49) 49
1st remission (48) 48
bone-marrow transplantation (48) 48
immunology (48) 48
hematopoietic stem cells (47) 47
adult patients (46) 46
cytosine-arabinoside (44) 44
aged, 80 and over (43) 43
cytogenetics (43) 43
follow-up studies (42) 42
daunorubicin (40) 40
cytarabine - therapeutic use (39) 39
hematology, oncology and palliative medicine (39) 39
colony-stimulating factor (38) 38
leukemia, myeloid - therapy (37) 37
leukemia (36) 36
survival (36) 36
cytarabine (35) 35
hematopoietic stem cell transplantation - methods (35) 35
minimal residual disease (35) 35
older patients (35) 35
antineoplastic agents - therapeutic use (34) 34
bone marrow transplantation (34) 34
combined modality therapy (34) 34
age factors (33) 33
leukemia, myeloid - mortality (33) 33
remission (33) 33
research (32) 32
therapy (32) 32
trial (32) 32
acute myeloblastic-leukemia (31) 31
karyotyping (31) 31
relapse (31) 31
child (30) 30
daunorubicin - administration & dosage (29) 29
leukemia, myeloid, acute - pathology (29) 29
analysis (28) 28
antineoplastic combined chemotherapy protocols - administration & dosage (28) 28
antineoplastic combined chemotherapy protocols - adverse effects (28) 28
prospective studies (28) 28
acute myelocytic-leukemia (27) 27
consolidation therapy (27) 27
induction (27) 27
acute promyelocytic leukemia (26) 26
chromosome aberrations (26) 26
consolidation chemotherapy (26) 26
acute lymphoblastic-leukemia (25) 25
kaplan-meier estimate (25) 25
etoposide - administration & dosage (24) 24
myelodysplastic syndrome (24) 24
abridged index medicus (23) 23
leukemia, myeloid, acute - diagnosis (23) 23
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Comparative Outcomes of Donor Graft CD34+ Selection and Immune Suppressive Therapy As Graft-Versus-Host Disease Prophylaxis for Patients With Acute Myeloid Leukemia in Complete Remission Undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transplantation
by Marcelo C. Pasquini and Steven Devine and Adam Mendizabal and Lindsey R. Baden and John R. Wingard and Hillard M. Lazarus and Frederick R. Appelbaum and Carolyn A. Keever-Taylor and Mary M. Horowitz and Shelly Carter and Richard J. O'Reilly and Robert J. Soiffer
Journal of Clinical Oncology, ISSN 0732-183X, 09/2012, Volume 30, Issue 26, pp. 3194 - 3201
Purpose T-cell depletion (TCD) reduces the incidence of graft-versus-host disease (GVHD) after hematopoietic cell transplantation (HCT). However, concerns... 
POSTREMISSION THERAPY | ONCOLOGY | BONE-MARROW-TRANSPLANTATION | BLOOD STEM-CELLS | HIGH-RISK | ACUTE MYELOGENOUS LEUKEMIA | TERM-FOLLOW-UP | RANDOMIZED-TRIAL | PERIPHERAL-BLOOD | T-CELL | NETWORK BMT CTN | Antigens, CD34 - metabolism | Humans | Immunosuppressive Agents - therapeutic use | Male | Treatment Outcome | Clinical Trials as Topic | T-Lymphocyte Subsets - metabolism | Female | Graft Rejection | Graft vs Host Disease - prevention & control | Hematopoietic Stem Cell Transplantation - methods | Lymphocyte Depletion - methods | Leukemia, Myeloid, Acute - therapy | Siblings | Original Reports | Bone1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Minimal residual disease-directed therapy in acute myeloid leukemia
by Kayser, Sabine and Schlenk, Richard F and Grimwade, David and Yosuico, Victor E. D and Walter, Roland B
Blood, ISSN 0006-4971, 04/2015, Volume 125, Issue 15, pp. 2331 - 2335
Case 1: A 35-year-old man with a normal white blood cell (WBC) count (9.3 3 10(9)/L) was diagnosed with acute myeloid leukemia (AML) with a t(8;21)(q22;q22)... 
POSTREMISSION THERAPY | PROGNOSTIC IMPACT | POLYMERASE-CHAIN-REACTION | KIT MUTATIONS | RISK STRATIFICATION | 1ST REMISSION | AML1-ETO-POSITIVE AML | UKALL 2003 | FUSION GENE TRANSCRIPTS | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Cytarabine - therapeutic use | Humans | Hematopoietic Stem Cell Transplantation | Male | Antineoplastic Agents - therapeutic use | Neoplasm, Residual - genetics | RUNX1 Translocation Partner 1 Protein | Leukemia, Myeloid, Acute - diagnosis | Oncogene Proteins, Fusion - genetics | Neoplasm, Residual - diagnosis | Adult | Female | Core Binding Factor Alpha 2 Subunit - genetics | Idarubicin - therapeutic use | Neoplasm, Residual - therapy | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. What's new in consolidation therapy in AML?
by Schlenk, Richard F and Jaramillo, Sonia and Müller-Tidow, Carsten
Seminars in Hematology, ISSN 0037-1963, 04/2019, Volume 56, Issue 2, pp. 96 - 101
Intensive induction chemotherapy followed by postremission treatment with either high-dose cytarabine-based regimens, autologous or allogeneic hematopoietic... 
YOUNGER PATIENTS | ADULT PATIENTS | GEMTUZUMAB OZOGAMICIN | POSTREMISSION THERAPY | IDH2 MUTATIONS | OLDER PATIENTS | HIGH-DOSE CYTARABINE | PROGNOSTIC RELEVANCE | ACUTE MYELOID-LEUKEMIA | HEMATOLOGY | MINIMAL RESIDUAL DISEASE
Journal Article
Details down arrow
4. Full Text Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)
by Tawfik, Bernard and Sliesoraitis, Sarunas and Lyerly, Susan and Klepin, Heidi D and Lawrence, Julia and Isom, Scott and Ellis, Leslie R and Manuel, Megan and Dralle, Sarah and Berenzon, Dmitriy and Powell, Bayard L and Pardee, Timothy
Annals of Hematology, ISSN 0939-5555, 1/2014, Volume 93, Issue 1, pp. 47 - 55
The hypomethylating agents (HAs), azacitidine and decitabine, have emerged as an alternative to initial and salvage therapy in patients with acute myeloid... 
Therapy | Unfit patients | Medicine & Public Health | Hematology | Azacitidine | Oncology | Decitabine | Acute myeloid leukemia | SINGLE-CENTER EXPERIENCE | INTENSIVE CHEMOTHERAPY | POSTREMISSION THERAPY | TRIAL | OLDER PATIENTS | LOW-DOSE CYTARABINE | GROUP-B | HEMATOLOGY | ELDERLY-PATIENTS | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Humans | Leukemia, Myeloid, Acute - metabolism | Middle Aged | Drug Evaluation | Salvage Therapy | Male | Neoplasm Proteins - antagonists & inhibitors | Consolidation Chemotherapy | DNA (Cytosine-5-)-Methyltransferases - antagonists & inhibitors | Leukemia, Myeloid, Acute - drug therapy | Female | Retrospective Studies | Azacitidine - administration & dosage | Comorbidity | Kaplan-Meier Estimate | Proportional Hazards Models | Azacitidine - analogs & derivatives | Survival Rate | DNA, Neoplasm - drug effects | Remission Induction | Azacitidine - pharmacology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | DNA Damage | DNA Methylation - drug effects | Cytogenetics | Analysis | Adults | unfit patients | acute myeloid leukemia | therapy | azacitidine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups
by Hengeveld, M and Suciu, S and Karrasch, M and Specchia, G and Marie, J.P and Muus, P and Petti, M.C and Rotoli, B and Amadori, S and Fioritoni, G and Leoni, P and Morra, E and Thaler, J and Resegotti, L and Fazi, P and Vignetti, M and Mandelli, F and Zittoun, R and Witte, T.J. de
Annals of Hematology, ISSN 0939-5555, 2012, Volume 91, Issue 6, pp. 825 - 835
The most effective post-remission treatment to maintain complete remission (CR) in adults aged between 46 and 60 years with acute myeloid leukaemia (AML) is... 
Acute myeloid leukaemia | Post-remission chemotherapy | CYTOSINE-ARABINOSIDE | POSTREMISSION THERAPY | COLONY-STIMULATING FACTOR | ACUTE MYELOGENOUS LEUKEMIA | 1ST REMISSION | HIGH-DOSE CYTARABINE | CHEMOTHERAPY | TRIAL | OLDER PATIENTS | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Hematology - organization & administration | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Consolidation Chemotherapy - methods | Humans | Middle Aged | Male | Medical Oncology - organization & administration | Societies, Medical - organization & administration | Young Adult | Maintenance Chemotherapy - methods | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Consolidation Chemotherapy - standards | Medical Oncology - methods | Europe | Induction Chemotherapy - methods | Treatment Outcome | International Cooperation | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hematology - methods | Maintenance Chemotherapy - standards | Adolescent | Italy | Anthracyclines | Mortality | Oncology, Experimental | Product development | Adults | Research | Comparative analysis | Standards | Cancer | cytarabine | Chemotherapy | Daunorubicin | Leukemia | Remission | Acute myeloid leukemia | Survival | Age
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study
by Ohtake, S and Miyawaki, S and Fujita, H and Kiyoi, H and Shinagawa, K and Usui, N and Okumura, H and Miyamura, K and Nakaseko, C and Miyazaki, Y and Fujieda, A and Nagai, T and Yamane, T and Taniwaki, M and Takahashi, M and Yagasaki, F and Kimura, Y and Asou, N and Sakamaki, H and Handa, H and Honda, S and Ohnishi, K and Naoe, T and Ohno, R
BLOOD, ISSN 0006-4971, 02/2011, Volume 117, Issue 8, pp. 2358 - 2365
We conducted a multi-institutional randomized study to determine whether high-dose daunorubicin would be as effective as standard-dose idarubicin in... 
TRIAL | MAINTENANCE INTENSIFICATION THERAPY | CYTOSINE-ARABINOSIDE | POSTREMISSION THERAPY | SOUTHWEST-ONCOLOGY-GROUP | ACUTE MYELOGENOUS LEUKEMIA | CONSOLIDATION THERAPY | MARROW-TRANSPLANTATION | CYTARABINE | HEMATOLOGY | CHEMOTHERAPY | Daunorubicin - therapeutic use | Cytarabine - therapeutic use | Humans | Middle Aged | Cytarabine - administration & dosage | Dose-Response Relationship, Drug | Leukemia, Myeloid, Acute - mortality | Young Adult | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Leukemia, Myeloid, Acute - drug therapy | Adult | Idarubicin - administration & dosage | Remission Induction - methods | Idarubicin - therapeutic use | Daunorubicin - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
by Venditti, A and Piciocchi, A and Candoni, A and Melillo, L and Calafiore, V and Cairoli, R and De Fabritiis, P and Storti, G and Salutari, P and Lanza, F and Martinelli, G and Luppi, M and Mazza, P and Martelli, MP and Cuneo, A and Albano, F and Fabbiano, F and Tafuri, A and Chierichini, A and Tieghi, A and Fracchiolla, NS and Capelli, D and Foa, R and Alati, C and La Sala, E and Fazi, P and Vignetti, M and Maurillo, L and Buccisano, F and Del Principe, MI and Irno-Consalvo, M and Ottone, T and Lavorgna, S and Voso, MT and Lo-Coco, F and Arcese, W and Amadori, S
BLOOD, ISSN 0006-4971, 09/2019, Volume 132, Issue 12, pp. 935 - 945
We designed a trial in which postremission therapy of young patients with de novo acute myeloid leukemia (AML) was decided combining cytogenetics/genetics and... 
AML | POSTREMISSION THERAPY | MANAGEMENT | HEMATOPOIETIC-CELL TRANSPLANTATION | STANDARD-RISK | RECOMMENDATIONS | CLASSIFICATION | PROGNOSTIC RELEVANCE | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | STRATIFICATION
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Maintenance therapy in acute myeloid leukemia: An evidence-based review of randomized trials
by Rashidi, Armin and Walter, Roland B and Tallman, Martin S and Appelbaum, Frederick R and DiPersio, John F
Blood, ISSN 0006-4971, 08/2016, Volume 128, Issue 6, pp. 763 - 773
INTENSIVE CHEMOTHERAPY | POSTREMISSION THERAPY | SOUTHWEST-ONCOLOGY-GROUP | ALLOGENEIC HSCT | ACUTE MYELOGENOUS LEUKEMIA | HIGH-DOSE CYTARABINE | QUALITY-OF-LIFE | RECOMBINANT INTERLEUKIN-2 | STEM-CELL TRANSPLANTATION | HEMATOLOGY | INTENSIFICATION THERAPY | Acute Disease | Immunotherapy - methods | Maintenance Chemotherapy - methods | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Humans | Survival Analysis | Quality of Life | Evidence-Based Medicine | Leukemia, Myeloid - therapy | Randomized Controlled Trials as Topic | Evidence-Based Focused Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification
by Komanduri, Krishna V and Levine, Ross L
Annual Review of Medicine, ISSN 0066-4219, 1/2016, Volume 67, Issue 1, pp. 59 - 72
The diagnosis and risk stratification of acute myeloid leukemia (AML) primarily rely on morphologic analysis and assessment of karyotype by chromosome banding... 
somatic mutation profiling | next-generation sequencing | induction chemotherapy | graft-versus-leukemia | postremission therapy | allogeneic hematopoietic stem cell transplantation | Graft-versus-leukemia | Somatic mutation profiling | Induction chemotherapy | Allogeneic hematopoietic stem cell transplantation | Next-generation sequencing | Postremission therapy | MEDICINE, RESEARCH & EXPERIMENTAL | MAINTENANCE CHEMOTHERAPY | THORACIC DUCT LYMPHOCYTES | ACUTE NONLYMPHOCYTIC LEUKEMIA | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOGENOUS LEUKEMIA | HEMOLYSIN-FORMING CELLS | MYELODYSPLASTIC SYNDROME | LOW-DOSE AZACITIDINE | STEM-CELL TRANSPLANTATION | Prognosis | Risk Assessment | Humans | Risk Factors | Hematopoietic Stem Cell Transplantation | Induction Chemotherapy | Consolidation Chemotherapy | Leukemia, Myeloid, Acute - diagnosis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Immunotherapy | Chromosome Aberrations | Mutation | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Revisiting maintenance therapy in acute myeloid leukemia with novel agents
by Canaani, Jonathan and Luger, Selina M
Current Opinion in Hematology, ISSN 1065-6251, 03/2016, Volume 23, Issue 2, pp. 175 - 180
PURPOSE OF REVIEWHigh relapse rates and therapy-related toxicity contribute to suboptimal outcomes in acute myeloid leukemia (AML) patients attaining a... 
tyrosine kinase inhibitors | maintenance therapy | acute myeloid leukemia | allogeneic bone marrow transplant | INTENSIVE CHEMOTHERAPY | POSTREMISSION THERAPY | ACUTE MYELOGENOUS LEUKEMIA | RECOMBINANT INTERLEUKIN-2 | COMBINATION | 1ST COMPLETE REMISSION | HIGH-DOSE LENALIDOMIDE | PHASE-II TRIAL | OLDER PATIENTS | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Humans | Hematopoietic Stem Cell Transplantation | Treatment Outcome | Combined Modality Therapy | Molecular Targeted Therapy | Remission Induction | Transplantation, Homologous | Leukemia, Myeloid, Acute - mortality | Retreatment | Leukemia, Myeloid, Acute - diagnosis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Leukemia, Myeloid, Acute - drug therapy | Maintenance Chemotherapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Risk-adapted induction and consolidation therapy in adults with de novo AML aged ≤ 60 years: results of a prospective multicenter trial
by Heil, G and Krauter, J and Raghavachar, A and Bergmann, L and Hoelzer, D and Fiedler, W and Lübbert, M and Noens, L and Schlimok, G and Arnold, R and Kirchner, H and Ganser, A
Annals of Hematology, ISSN 0939-5555, 6/2004, Volume 83, Issue 6, pp. 336 - 344
We treated 305 de novo acute myeloid leukemia (AML) patients aged ≤60 years with risk-adapted therapy. Patients with CBF leukemias or normal karyotype and good... 
Medicine | AML | Early response | Karyotype | Risk-adapted therapy | risk-adapted therapy | POSTREMISSION THERAPY | COMPLETE REMISSION | early response | ACUTE MYELOGENOUS LEUKEMIA | RANDOMIZED-TRIAL | HIGH-DOSE CYTARABINE | COOPERATIVE GROUP | ACUTE MYELOID-LEUKEMIA | CHEMOTHERAPY | karyotype | HEMATOLOGY | PROGNOSTIC FACTOR | ACUTE PROMYELOCYTIC LEUKEMIA | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cytarabine - adverse effects | Stem Cell Transplantation | Idarubicin - adverse effects | Karyotyping | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Idarubicin - administration & dosage | Amsacrine - adverse effects | Daunorubicin - administration & dosage | Leukemia, Myeloid, Acute - therapy | Etoposide - adverse effects | Risk Assessment | Leukemia, Myeloid, Acute - pathology | Etoposide - administration & dosage | Amsacrine - administration & dosage | Combined Modality Therapy | Remission Induction | Cytarabine - administration & dosage | Daunorubicin - adverse effects | Adolescent | Survival Analysis | Bone marrow | Medical research | Consolidation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Adults: An Evidence-based Review
by Hahn, Theresa and Wall, Donna and Camitta, Bruce and Davies, Stella and Dillon, Hildy and Gaynon, Paul and Larson, Richard A and Parsons, Susan and Seidenfeld, Jerome and Weisdorf, Daniel and McCarthy, Philip L
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2006, Volume 12, Issue 1, pp. 1 - 30
Evidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy of acute lymphoblastic leukemia in adults (≥15 years) is presented... 
Therapy | Adult | Acute lymphoblastic leukemia | Hematopoietic stem cell transplantation | TOTAL-BODY IRRADIATION | POSTREMISSION THERAPY | MAINTENANCE CHEMOTHERAPY | therapy | BONE-MARROW-TRANSPLANTATION | SINGLE-CENTER | IMMUNOLOGY | 1ST COMPLETE REMISSION | TRANSPLANTATION | acute lymphoblastic leukemia | HIGH-RISK | hematopoietic stem cell transplantation | TERM-FOLLOW-UP | adult | HEMATOLOGY | INTENSIVE CONSOLIDATION | HIGH-DOSE ETOPOSIDE | Graft vs Leukemia Effect | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Humans | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Treatment Outcome | Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis | Hematopoietic Stem Cell Transplantation - methods | Evidence-Based Medicine | Practice Guidelines as Topic | Care and treatment | Oncology, Experimental | Transplantation | Research | Antineoplastic agents | Evidence-based medicine | Hematopoietic stem cells | Antimitotic agents | Stem cells | Adults | Lymphomas | Acute lymphocytic leukemia | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Cytarabine Dose for Acute Myeloid Leukemia
by Löwenberg, Bob and Pabst, Thomas and Vellenga, Edo and van Putten, Wim and Schouten, Harry C and Graux, Carlos and Ferrant, Augustin and Sonneveld, Pieter and Biemond, Bart J and Gratwohl, Alois and de Greef, Georgine E and Verdonck, Leo F and Schaafsma, Martijn R and Gregor, Michael and Theobald, Matthias and Schanz, Urs and Maertens, Johan and Ossenkoppele, Gert J and Swiss Grp Clinical Canc Res SAKK and Dutch-Belgian Cooperative Trial and Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group
The New England Journal of Medicine, ISSN 0028-4793, 03/2011, Volume 364, Issue 11, pp. 1027 - 1036
High-dose cytarabine is up to 30 times the standard dose of this drug. Although more effective, the higher dose is more toxic. In this study, an intermediate... 
CYTOSINE-ARABINOSIDE | MEDICINE, GENERAL & INTERNAL | COLONY-STIMULATING FACTOR | INDUCTION THERAPY | 1ST REMISSION | REPETITIVE CYCLES | ADULTS | POSTREMISSION CHEMOTHERAPY | GROUP-B | DAUNORUBICIN | INTENSIFICATION | Prognosis | Humans | Middle Aged | Proportional Hazards Models | Male | Combined Modality Therapy | Cytarabine - adverse effects | Remission Induction | Cytarabine - administration & dosage | Antimetabolites, Antineoplastic - administration & dosage | Leukemia, Myeloid, Acute - mortality | Stem Cell Transplantation | Young Adult | Adolescent | Antimetabolites, Antineoplastic - adverse effects | Intention to Treat Analysis | Survival Analysis | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Leukemia, Myeloid, Acute - therapy | Dosage and administration | Cytarabine | Studies | Consolidation | Medical treatment | Age | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights